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Abstract 
Several inhibitors of the arachidonic acid-metaboliz-
ing enzyme, 5-lipoxygenase reduce proliferation of hem-
atopoietic and non-hematopoietic cells and cell lines and 
some cells undergo limited differentiation. Cells were 
cultured from patients with chronic myelogenous leuke-
mia in "blast" crisis with the selective inhibitor of 5-
lipoxygenase,SC41661A[3-{3 ,5-bis(l, 1-dimethyl)-4-hy-
droxyphenyl}hiol]-N-methyl-N-[2-(2-phridinyl-propana-
mide)]. Cells cultured for 3 to 5 days with 40 µM 
SC41661A exhibited reduced cellular numbers along 
with ultrastructural changes and DNA laddering charac-
teristic of apoptosis. Similar culture conditions reduced 
proliferation of U937 monoblastoid cells. In U937 cells, 
the ultrastructural features of apoptosis were not ob-
served at 72 hours, when DNA laddering was present 
and cell numbers were reduced, but was present after 
144 hours of culture. Dissociation between certain mor-
phologic and biochemical sequelae of apoptosis has been 
described in other systems. These observations are of 
interest since the induction of apoptosis in dividing 
chronic myelogenous leukemia (CML) cells by a non-
cytotoxic agent suggests paradigmatically new sites for 
therapeutic intervention. 
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Introduction 
Myelogenous leukemia cells from patients and the 
HL60 myelomonocytic and U937 monoblastoid cell lines 
express the arachidonic acid-metabolizing enzyme, 5-
lipoxygenase [2]. This enzyme forms the hydroperoxy 
and hydroxy intermediates, 5-HPETE, 5-HETE, and 
leukotriene A4, leading to LTB4 (via LT4A hydrolase), 
LTC4 (by LTC4 synthetase) and LTD4 (due to gamma-
glutamyl-peptidase), which can be subsequently cleaved 
by various dipeptidases to yield LTE4. While most of 
the biological effects of leukotrienes have been identified 
in studies of immune function and smooth muscle con-
traction, a role in modulating proliferation of at least 
some types of cells is a distinct possibility. Malignant 
cells from patients with chronic myelogenous leukemia 
synthesize excess amounts of leukotriene C4 [20]. 
Patients with myelogenous leukemia usually can be 
maintained for some time with several forms of therapy, 
but eventually the disease recurs and proliferating leu-
kemia cells appear in the circulation. These cells are 
unresponsive to agents as employed previously and can 
be refractory to new therapy [9]. 
In the present study, we observed the induction in 
vitro of apoptosis in chronic myelogenous leukemia 
(CML) cells from paJients in "blast" crisis by a selective 
non-cytotoxic inhibitor of 5-lipoxygenase [3, 10], 
SC41661A [3-{3 ,5-bis(l, 1-dimethyl)-4-hydroxyphenyl} 
thiol]-N-methyl-N-[2-(2-phridinyl-propanamide) }Jssoci-
ated with abortive attempts at expression of a differen-
tiated function. While the mechanism of this response 
is unknown, the ability to access an apoptotic pathway 
inherent in myelogenous leukemia cells that have es-
caped first and often second-line therapy by a non-cyto-
toxic agent suggests future sites for therapeutic interven-
tion. 
Materials and Methods 
Myelogenous leukemia cells from patients in blastic 
crisis or U937 monoblastoid cells were maintained in 
suspension culture by serial dilution every 3 to 4 days 
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Table 1. Effect of SC41661A on the 4 hour incorpora-
tion of 3H-thymidine (cpm ± standard deviation, SD) 
into DNA of peripheral blood cells from patients with 
CML in blastic crisis and into U937 monoblastoid cells. 
N (number of samples) = 4 for each data point. Repre-
sentative examples are presented. More extensive data 
are presented in references [3, 4]. 
CML cells U937 cells 
Control 2063 ± 196 10406 ± 296 
SC41661A 
20µM 1743 ± 219 4728 ± 322 
40 µM 1324 ± 386 3673 ± 640 
80 µM 525 ± 40 233 ± 26 
Table 2. The effect of 40 µM SC41661A on cell num-
bers after 5 days of culture (x 10·4/ml). N = 2. Repre-
sentative experiments are presented and more extensive 




1.25 ± 0.34 
0.04 ± 0.03 
U937 cells 
66.9 ± 9.2 
27.4 ± 6.8 
with RPMI (Rosewell Park Memorial Institute, Buffalo, 
NY) 1640 medium containing 5 % fetal bovine serum 
(FBS; U937) or 10% FBS (CML), 24 mM HEPES {N-
(2-hydroxyethyl) piperazine-N' (2-ethylsulfonic acid)}, 
2 mM glutamine, 50 µgfml streptomycin and 50 units/ 
ml penicillin [17]. Before culture, cells from patients 
were first purified on Ficoll gradients. Cell lines were 
treated in log phase with 40 µM SC41661A in dimethyl-
sulfoxide (DMSO; 1 µI/ml medium) after a 1:2 split 
with medium for 24 hours; in some experiments, incor-
poration of 3H-thymidine was measured after 4 hours, in 
others cells were cultured for an additional 48 to 120 
hours before samples were taken for cell counts and 
DNA electrophoresis. 
Transmission electron microscopy (TEM) was per-
formed according to conventional procedures including 
fixation in glutaraldehyde (2.5 % in cacodylate buffer, 
pH 7 .4) containing 4 % sucrose for 2 hours at room tem-
perature [1]. Subsequently they were washed in buffer, 
post-fixed with 1 % osmium tetroxide for 1 hour, rinsed 
in buffer, stained for 1 hour in uranyl acetate, dehy-
drated with increasing concentrations of ethanol and 
propylene oxide and embedded in epon/araldite. Grids 
were stained with Reynold's lead and uranyl acetate and 
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Figure 1. Control cells from a patient with CML in 
blastic crisis. Bar = 2 µm. 
Figure 2. Apoptotic cells with extensive cytoplasmic 
vacuolation and several others with extensively con-
densed chromatin with little residual cytoplasm. One 
cell with marginated chromatin may represent a necrotic 
cell. Bar = 2 µm. 
sections examined with either a Siemens's 101 or a 
100 ex TEM. 
DNA was isolated with a DNA/RNA isolation kit 
(United States Biochemical Co, Cleveland, OH) accord-
ing to the accompanying instructions. Cells were 
centrifuged, washed and lysed with lysis buffer. After 
adding the extraction buffer, the aqueous phase was 
transferred to another tube and sodium acetate and iso-
propanol used to precipitate DNA. DNA was resus-
pended in TE buffer and incubated with DNase-free 
RNase at 40°C for 1 hour. Samples (2-5 µg DNA each) 
were electrophoresed on O. 8 % agarose gels containing 
ethidium bromide (0.5 µgfml gel) at 70-90 volts for 1.5 
to 2 hours, bands visualized with ultra-violet light and 
photographed with a Polaroid camera. 
Work in progress employed an Apoptag kit from 
Oncor, Gaithersburg, VA. 
Results 
SC41661A reduced the proliferation of CML blast 
cells from patient's peripheral blood and of U937 mono-
blastoid cells in a concentration-dependent manner 
(Table 1). These results are typical of those reported in 
ref. [3, 4]; a lesser number of studies of the myeloblast 
HL60 cell line with similar results are in progress (re-
sults not shown). The concentration of SC41661A em-
ployed was 1 to 2 times the IC50 which inhibits PMN 5-
lipoxygenase activity [15]. Uptake of trypan blue at 4 
hour was unchanged in control and experimental groups 
(not shown). SC41661A is not considered to be cyto-
toxic [3, 4, 10, 15]. Cell counts after 3 or more days 
were greatly reduced in drug-treated cultures (Table 2; 
results are representative of additional experiments 
reported in ref. [3, 4]). 
Aliquots of CML cells cultured for 5 days with 
SC41661A were removed for cell counts, viability and 
transmission electron microscopy. Over half the cells 
stained with trypan blue and cellular debris was present. 
There was little evidence of apoptosis in control 
CML cells (Fig. 1) and only occasional (less than sever-
al percent) cells exhibited structural changes consistent 
with that process. SC41661A-treated cultures contained 
50 percent or more cells exhibiting features of apoptosis 
Apoptosis in human leukemia 
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(Figs. 2-7). These included shrunken cells containing 
typical nuclear apoptotic changes of condensed chroma-
tin (Fig. 2) progressing to crescent-shaped accumulations 
in some cells and globular accretions in others (Figs. 3 
and 4). Increasingly extensive cytoplasmic vacuolation 
occurred, some vacuoles representing what are interpret-
ed as developing primary granules (Fig. 6). These rep-
resent differentiated structures consisting of vesicles 
containing inactive degradative enzymes related to im-
mune defence and characteristic of more mature granulo-
cytes [6]. In some cells, precipitated chromatin ap-
peared to leak into the residual cytoplasm after dissolu-
tion of the nuclear membrane (Fig. 6), compared with 
other end-stage cells in which elements of chromatin re-
mained attached to the nuclear membrane (Fig. 7). 
Generally mitochondria were well preserved until later 
stages of the process, when a variety of pycnotic frag-
ments remained. In some cells, cytoplasmic vacuolation 
was more extensive than nuclear changes (Figs. 2 and 
3). Either other regions of their nuclei with apoptotic 
changes were missed in the sectioning or such changes 
were absent. Other cells apparently remained unaffected 
by the drug (Figs. 4, 5, and 7). Many of the apoptotic 
cells were in the later stages of dissolution when changes 
of necrosis may be present. 
One of a number of samples of CML cells from pa-
tients in blastic crisis cultured for 3 days with 40 µ.M 
SC41661A and examined for DNA laddering is present-
ed in Figure 8A. Lower molecular weight multiples of 
DNA are present in this and in other comparable sam-
ples (not shown). We believe that laddering in the pres-
ence of SC41661A follows cessation of DNA synthesis, 
so that susceptible cells either were in or enter a prolif-
erative stage of the cell cycle which is inhibited by the 
drug. Presently too few samples are available to defi-
nitely correlate the extent of proliferation as judged by 
the percentage of blast cells and DNA laddering. 
Several ultrastructural studies of U937 cells cultured 
for 3 days with SC41661A have been done [e.g., 4]. 
Cytoplasmic or nuclear changes consistent with apoptosis 
were not seen. More recently U937 cell_s cultured with 
SC41661A for 120 hours were found to exhibit nuclear 
and cytoplasmic ultrastructural changes consistent with 
apoptosis (work in progress, not shown). 
Although ultrastructural studies of U937 cells cul-
tured for 72 hours provided no evidence of necrosis or 
apoptosis, DNA laddering was sought, employing 0.8 % 
agarose gel electrophoresis and staining with ethidium 
bromide (Fig. 8B.). U937 cells cultured with 40 µ.M 
SC41661A for 3 days and compared with the DMSO 
(vehicle) control exhibited DNA laddering consistent 
with apoptosis in preparations in which cell numbers 
were reduced compared with controls. When analyzed 
with the Apoptag kit that identifies free 3 '-OH termini 
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Figure 3. An apoptotic cell with crescent-shaped con-
densed chromatin, another cell with extensive cytoplas-
mic vacuolation and little nuclear change evident. Bar 
= 2 µ.m. 
Figure 4. An apoptotic cells with extensively condensed 
chromatin, portions of which appear to be invaded by 
cytoplasmic vacuoles. Bar = 2 µ.m. 
of DNA, intense brown staining indicating these free 
termini was present in nuclei of SC41661A-treated U937 
cells with lesser staining of their cytoplasm, consistent 
with the presence of DNA at that site (not shown, work 
in progress). These results will be presented in a 
subsequent communication. 
Discussion 
Discrepancies between characteristic morphologic 
changes of apoptosis and DNA laddering have been de-
scribed [7, 8, 11, 13]. IfDNA degradation is not exten-
sive with the generation of oligosomes, laddering may 
be absent in the presence of typical nuclear morphologic 
changes [13]. In studies of embryonic systems, exten-
sive cytoplasmic changes consistent with apoptosis have 
been noted in the absence or a delayed presence of nu-
clear chromatin changes [7, 11, 22]. Features of both 
necrosis and apoptosis may occur in different cells or in 
the same cells and necrotic changes may be present as 
an end stage of apoptosis. In addition, DNA laddering 
has been reported to occur in cells undergoing necrosis 
[8]. These variations depend upon the system studied 
and conditions employed [5]. 
The kinetics of apoptosis, in some systems occur-
ring from 20 minutes to perhaps an hour and the percent 
of cells involved before or during this interval will de-
termine if apoptotic cells are detected by morphology, 
DNA laddering, or both. Apoptosis of only several per-
cent of cells in a population can be sufficient to produce 
DNA laddering. Whether cells from all or only some 
stages of the cell cycle can be induced to access an 
apoptotic program also depends upon the system studied 
[16]. The rate at which high molecular Weight DNA is 
degraded to oligomers should determine the ability to 
detect apoptosis by these means. A prolonged half-life 
of "nicked" high molecular weight DNA should favor 
"capping" or other large scale DNA accumulations [13], 
and characteristic nuclear DNA changes should be more 
readily detected by electron microscopy, as seems to be 
the case with CML blast cells. The presence of cyto-
plasmic changes consistent with apoptosis without typical 
nuclear changes [7, 11, 22] suggests that components of 
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Figure 7 (above). End stage of apoptotic cell dissolution with residual nuclear chromatin bodies. Bar = 2 µm. 
·---------------------------------------------------------------------------------------------
Figure 5 (on the facing page). Apoptotic cells with 
what appear to be swollen developing primary granules, 
a measure of differentiation. Bar = 2 µm. 
Figure 6 (on the facing page). Apparent dissolution of 
the nuclear membrane with release of condensed chro-
matin into the remaining cytoplasm. Bar = 2 µm. 
the apoptosis "program" can be dissociated and individu-
ally activated. Some of these variations may depend 
upon karyotypic changes in the leukemia cell population, 
with development of progressively more aneuploid chro-
mosomes determining some of their phenotypes. If dur-
ing apoptosis affected cells exhibit some indeterminate 
marginated clumping of chromatin, swelling of the cyto-
plasm and its organelles with flocculent densities 
appearing within mitochondria, these changes would in-
dicate accompanying necrosis which could confound the 
interpretation. 
Most patients in blastic crisis have been on a main-
tenance therapy that has become unable to control the 
disease. Depending upon circumstances, the sample 
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provided by the clinician may have been drawn before 
institution of new and possibly more successful therapy, 
or at some time thereafter. Following chemotherapy or 
radiation, apoptosis is a major mechanism of cell killing 
and apoptotic cells could be present in the control sam-
ples from effectively treated patients. These factors can 
complicate interpretation of these studies and may be the 
reason for some DNA laddering in control samples. An 
absence of actively proliferating cells may account for 
any lack of DNA laddering in drug-treated cultured 
cells, but this point needs to be examined with a larger 
number of samples containing differing percentages of 
replicating CML cells. 
We now take up the issue of a proposed mechanism 
for these results. Do we believe that inhibition of 5-
lipoxygenase by concentrations of a selective inhibitor 
that are 1 to 2 times the IC50 of the enzyme in mature 
granulocytes is responsible? It can be suggested that one 
or more products of 5-LP0x serve as an autocrine or 
paracrine growth factor, thereby expressing anti-apopto-
tic activity, or modulate the activity of such agents. 
There are precedents for this, since leukotriene products 
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Figure 8. DNA laddering of CML blast cells (A, at left) and of U937 cells (B, at right) cultured with 40 µM 
SC41661A for 48 and 120 hours, respectively. D: DMSO control, middle lanes; SC: SC41661A, left lanes; DNA 
standard: lambda Hin dIII from 23.1 to 0.6 kB (faint lower band), right lanes. 
have been reported to serve the latter function [ reviewed 
in ref. 2]. However, suramin, employed in the treat-
ment of metastatic prostate cancer provides an instruc-
tive cautionary example. Originally reported to inhibit 
the interaction between epidermal growth factor and its 
receptor, more recently it was also shown to impair 
mitochondrial oxidative metabolism, prqviding a dual in-
hibitory effect on cellular proliferation [18]. It would 
not be surprising if besides inhibiting 5-LP0x, which is 
expected at the concentrations of SC41661A we employ 
[15], additional biochemical events may occur that con-
tribute to suppression of proliferation and induction of 
apoptosis [15]. Originally Wickremasinghe et al. [21] 
reported that MK866, a unique inhibitor of 5-LP0x 
"tethering" to membranes (required for enzyme function) 
did not reduce proliferation of cells known to contain 5-
LP0x, while other inhibitors of the enzyme that included 
oxidation/reduction agents were able to inhibit prolifera-
tion of cells in which 5-LP0x was considered to be ab-
sent. However, subsequently they reported that MK866 
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inhibited proliferation of CML cells from 40 % of the pa-
tient samples studied, indicating that replication of CML 
cells in this large subset was dependent upon functional 
5-LP0x activity [14]. 
It is certainly possible that SC41661A at 40 µMin-
hibits this subset of replicating CML cells because of its 
anti 5-LP0x activity, but in addition reduces the rate of 
proliferation of the other 60 percent of CML cells by 
additional mechanisms yet to be identified. Cells appar-
ently unaffected by the drug may not have been cycling, 
which may be a prerequisite for its channelling of the 
cells into apoptosis. Antitumor effects of 5-LP0x have 
been examined in at least two in vivo studies. Nafaza-
trom (Bay q 6575) (at 0. 8 mg/kg) inhibited the growth 
of B16 melanoma cells in nude mice by 90 percent [12], 
while SC41661A at 1.15 mg/mouse i.p. protected nude 
mice from OVCAR human ovarian carcinoma cells [10] 
without cytotoxic effects on the animals. SCIO (severe 
combined immunodeficient) mice that receive human 
CML cells intravenously exhibit a disease mimicking 
Apoptosis in human leukemia 
human leukemia and may represent a suitable model in 
which to test any antileukemic effects of 5-LP0x 
inhibitors [19). Whether SC41661A or other inhibitors 
of 5-LP0x are active in vivo, they may sensitize leuke-
mia or other malignantly transformed cells to chemother-
apy, biological response modifiers or radiation therapy. 
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Discussion with Reviewers 
A. Liepins: In the text you say: "SC41661A-treated 
cultures contained 50 percent or more cells exhibiting 
features of apoptosis (Figs. 2-7)"; what are the "features 
of apoptosis"? 
Authors: Generally, it is agreed that cells undergoing 
apoptosis decrease in size, nuclear changes of unusual 
condensations of chromatin occur, followed by intemu-
cleosomal scission and release of oligomeric nucleoso-
mal arrays. Cytoplasmic "apoptotic" vesicles appear but 
generally, organelles such as mitochondria are relatively 
unaffected until later in the process. Phagocytosis of af-
fected cells and cell remnants occurs in vivo; in vitro, 
without exposure to scavenger cells, disruption also oc-
curs with release of vesicular material at times contain-
ing residual nuclear chromatin. As mentioned below, 
programmed cell death occurring in embryonic systems 
need not express all of these features [7, 8, 11, 13, 22]. 
A. Liepins: In the text you also say: "Increasingly 
extensive cytoplasmic vacuolation occurred, some vacu-
oles representing what are interpreted as developing pri-
mary granules (Fig. 6)"; what are "primary granules"? 
Authors: "Primary granules" normally begin to appear 
in the cytoplasm of leukocytes during very early differ-
entiation, and structures that fulfill this description were 
seen in SC41661A-treated CML cells. When fully dif-
ferentiated, such bodies contain various degradative en-
zymes used in the host defence against bacteria and 
other engulfed foreign bodies. Please see reference [6] 
for further information about these structures. 
E. Falcieri: Why did you use 4% sucrose in the fixa-
tive? Can you exclude an osmotic effect on the cell? 
Authors: Use of 4% sucrose in the fixative is intended 
to avoid osmotic effects and is a fairly standard 
technique in a number of laboratories. 
E. Falcieri: It is well known that frequently the apopto-
tical process is followed by a "secondary necrosis". 
This is characterized by a progressive hydration of 
cytoplasm and organelles, with initially minimal nuclear 
involvement. Plasma membrane and organelle disrup-
tion successively appear, allowing the lysosomal content 
to leak out into the cytoplasm. In the apoptotic cell un-
dergoing necrosis, only apoptotic nucleus can be recog-
nized in the final stage. If assumed that apoptotic cells 
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are characterized by strongly clustered or condensed 
chromatin, in most images presented in the paper late 
apoptotic features appear. How could the authors ex-
plain this behaviour? Why did you not see typical 
"early" apoptotic patterns long described in the litera-
ture? 
Authors: We agree that many of the apoptotic changes 
in the CML cells are relatively late; the most likely 
reason why we did not see early changes was the choice 
of 120 hours of drug treatment before isolation of cells 
for electron microscopy. It may be that accession of 
apoptosis is cell cycle-dependent and cells are only 
gradually accumulated in the appropriate (S?) phase of 
the cycle prior to "exit" into apoptosis. This answer to 
this question is being studied with U937 cells. The use 
of CML blast cells is more difficult due to (a) the rela-
tive infrequency of samples, and (b) requirement for 
ancillary growth factors such as IL3 and GM-CSF to 
achieve maximum in vitro cell replication which, due to 
their cost were not used. 
The distinction between middle to late apoptosis and 
its end-stage when secondary necrosis can be present is 
not always easy to make. This is why, ideally, as many 
distinct features of the process, morphologic, biochemi-
cal and cell-biological/functional, as can be adduced to 
support the claim should be accumulated. The concept 
of apoptosis, whether it is distinct from programmed cell 
death, the appearance of what seems to be laddering of 
DNA from cells induced to undergo necrosis [8], the 
separation of DNA events in apoptosis from attempts at 
conservative DNA replication, and DNA repair reac-
tions, have not been studied extensively, at least not all 
in the same system. Whether induction of apoptosis is 
cell type-dependent, inducible from all or only from cer-
tain stages of the cell cycle, which protooncogenes, P53, 
bcl-2, C-myc, C-fos, the RB gene participate in the vari-
ous systems studied have not been coordinated into a 
common scheme. It is also true that cells induced to un-
dergo necrosis by several means can exhibit "classic" 
DNA laddering [8]. For these and other reasons, a 
"final" common definition of "apoptosis" has not yet 
been developed. Since considerable variation among af-
ferent signalling systems have been and, possibly less 
likely the efferent effector pathway(s) will be found, 
differences in detail among various pre and post-embry-
onic types of cells may preclude a common definition. 
E. Falcieri: How do you interpret those cells with cyto-
plasmic alterations but without evident nuclear changes? 
Authors: A number of cells exhibited cytoplasmic 
changes without evident nuclear alterations. That may 
have been due to sampling and the manner in which 
cells and their nuclei were sectioned. Alternately, in 
some aberrant transformed cancer cells, the agent em-
Apoptosis in human leukemia 
ployed might activate pre or post-nuclear events which 
bypass that organelle, leading to "downstream" cytoplas-
mic apoptotic events, as suggested to occur in certain 
forms of programmed cell death without early nuclear 
changes. Conceivably, the karyotypic changes in chron-
ic leukemic cells undergoing blastic crisis "uncouple" 
some of the nuclear and cytoplasmic events observed in 
apoptosis of non-transformed cells with normal karyo-
types. Possibly relatively undifferentiated cells utilize a 
"programmed cell death" pathway more akin to cell 
death occurring in some embryonic systems. This is an 
interesting question worth more thought. 
M. Rubenstein: No biochemical markers such as the 
amount of bcl-2 protein or mRNA are used, nor is end 
group analysis using 3' terminal transferase labelling of 
fragmented DNA. 
Authors: Bcl-2 protein is not a general "marker" for 
apoptosis, and for some types of cells, does not seem to 
be involved in the process. In other systems, it may 
retard or even prevent the process, but it is not thought 
to be a universally active antiiapoptotic agent in all types 
of cells. Studies with an end-labelling kit have been 
performed and will be reported separately. 
J.A. Kellen: ... However, in order to consider in vivo 
studies, the effect of SC41661A could (and should) be 
tested by flow cytometry of control and treated cell 
cultures ( ... such as in Telford et al., J. Immunolog. 
Methods, 172, 1-16, 1994). 
Authors: Flow cytometry is certainly another means of 
measuring DNA degradation. For some studies, espe-
cially those of the cell cycle susceptibility to apop-
tosis-inducing agents, use of the technique is ideal and 
such studies are in progress with U937 cells. 
J.A. Kellen: Perhaps an indication as to the mecha-
nism(s) of multiple drug resistance (MDR) would be 
appropriate in the Introduction. 
Authors: We do not believe that discussion of multiple 
drug resistance is indicated for this paper. Resistance to 
drug-induced apoptosis, as distinct from drug resistance 
due to MDR may represent one of the numerous forms 
of "drug resistance". No studies of MDRl protein or 
RNA synthesis were performed. Reasons why apoptosis 
is readily induced in some and not in other types of can-
cer is a large! y unknown area of study, since the afferent 
and efferent signal transduction pathways and effector 
molecules for these events often differ among systems 
studied and generally are not well defined. 
J.A. Kellen: In the text you say "There was little evi-
dence of apoptosis in control CML cells (Fig. 1) ... " -
by EM! Obviously, there must be some apoptosis, but 
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was just not evident in the sample studied. Is less than 
5 % consistent with generally accepted numbers in 
leukemic cell cultures. 
Authors: In control samples, we did not find a signifi-
cant number of morphologically apoptotic cells (i.e., 
more than several percent, a "rare" cell was seen). 
Faint DNA laddering could at times be seen in some cul-
tured control samples but less than that from treated 
samples exhibiting reduced numbers of cells. It has 
been reported that several percent of apoptotic cells in a 
population is sufficient to yield DNA banding. In other 
words, it depends upon the clinical setting and a priori, 
no rules are guaranteed. If patients have recently been 
effectively treated, significant apoptosis might be expect-
ed; if they are in true blastic crisis with major prolifera-
tion of blast forms, spontaneously apoptotic cells may be 
"lost" among the dividing forms unless their frequency 
is augmented by treatment. Non-dividing CML cells 
may not be susceptible to SC41661A-induced apoptosis. 
J.A. Kellen: In connection with Table 2 you say in the 
text: "... results are representative ... ". What is 
"representative"? Are these electron micrographs of the 
most characteristic and typical areas and samples or are 
they a typical average findings (from how many scans)? 
Authors: "Representative" electron photomicrographs 
include areas from apoptotic cells selected by an experi-
enced electron microscopist that characterized the major-
ity of the apoptotic cells observed. As mentioned, other 
cells did not exhibit typical nuclear changes while pre-
senting cytoplasmic fmdings consistent with apoptosis 
and a few cells appeared to be unaffected by the drug 
(discussed above). Whether the former represents pro-
grammed cell death in which extensive nuclear changes 
are not present, at least not early in the process, is 
unclear. Cells that appeared to be unaffected by the 
agent may never have been in cell cycle, which we be-
lieve but have not demonstrated, may be a requirement 
for SC41661A-induced CML cell apoptosis. Possibly 
malignantly transformed CML cells, in which normal 
differentiation is "blocked", express a more embryonic 
form of "programmed" cell death as a dysfunctional 
phenotype, as suggested above. 
I.D. Bowen: The authors should note that other investi-
gators have discovered inconsistency between the mor-
phological symptoms of apoptosis and the incidence of 
DNA ladders (Bursch et al., 1992; Zakeri et al., 1993) 
to the extent that DNA laddering is being questioned as 
being diagnostic for apoptosis (Bowen, 1993). 
Authors: The papers of Collins et al. (1992), Gershen-
son and Rotello (1992), Bowen (1993), and Zakeri et al. 
(1993) discuss these more recent findings and their inter-
pretation. Apoptosis or programmed cell death in can-
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cer cells may present special problems of interpretation. 
Malignantly transformed cells such as CML or 
U937 cells in some sense "revert" to more (or are devel-
opmentally incapable of maturing from) "primitive" dif-
ferentiation states in which apoptosis may not recapitu-
late the typical findings reported for mature cycling or 
terminally differentiated cells. Programmed cell death 
without typical DNA laddering (or with delayed ladder-
ing) may represent an earlier "precursor" form of non-
necrotic cell destruction in developmentally arrested 
malignantly transformed cells. Whether various afferent 
or efferent pathways involved in either process can be 
accessed by non-cytotoxic means could be of considera-
ble interest to those wanting to modify the biology of 
cancer cells. 
J.A. Kellen: In Table 2, surely "(x 10-4/ml)" means 
10,000 cells/ml and should read lo4/ml. 
Authors: In the biochemical literature, a value of 
10,000 generally is represented in tabular form as, e.g., 
(cpm x 10-4). Thus, 12.0 stands for 120,000 x 10-4 = 
12.0. 
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